Ketamine as a Depression Treatment: What Is and Isn’t Known

What’s Established

Ketamine’s use as a depression treatment represents one of the more significant developments in psychiatry in recent decades, precisely because of how it works and how fast it can work — both distinct from conventional antidepressants.

Standard antidepressants, like SSRIs, typically take four to six weeks to produce a noticeable effect, and work primarily through serotonin pathways. Ketamine acts through a different mechanism entirely — primarily as an NMDA receptor antagonist — and its antidepressant effects can appear within hours of a single dose in some patients, a genuinely unusual property in psychiatric treatment. This rapid-acting quality is part of why ketamine has been studied specifically for patients with treatment-resistant depression, meaning depression that hasn’t responded adequately to at least two different standard antidepressant trials, and for patients experiencing acute suicidal ideation, where a fast-acting option carries obvious clinical value.

The evidence base supporting short-term efficacy is genuinely substantial at this point. Multiple randomized, double-blind, placebo-controlled trials support ketamine’s short-term antidepressant effects across a range of populations, including adolescents, elderly patients, postpartum populations, and general treatment-resistant depression cohorts.

What’s Still Being Researched

A genuinely important gap in the current evidence: most of the strong trial data addresses short-term outcomes — typically measured in days to a few weeks after treatment — rather than durability over months or years. How to maintain a response over the longer term, whether through repeated maintenance dosing, switching to a different formulation, or another approach entirely, remains an active area of study rather than a settled question.

The comparative picture between racemic ketamine and esketamine specifically is also less settled than the existence of two approved-and-used products might suggest. As of recent reviews, no large-scale trial has directly randomized patients between racemic ketamine and esketamine head-to-head under matched conditions — most of the comparative evidence comes from indirect meta-analytic comparison across separate trials rather than a single head-to-head study, which is a meaningfully weaker form of evidence. Researchers have specifically called for such a trial; it hadn’t been conducted as of the most recent literature reviewed for this article.

Finally, arketamine’s clinical development in humans remains at an earlier stage than esketamine’s. Preclinical and animal studies suggest real promise — greater potency and longer-lasting antidepressant-like effects than esketamine, with fewer side effects, in these models — but human clinical trial data is more limited, and arketamine isn’t available as an approved treatment anywhere at this time. Whether the preclinical advantages translate into humans is a live research question rather than an established fact.

What This Means in Practice

For someone considering ketamine treatment for depression today, the practical takeaway from where the evidence currently stands:

• Ketamine has short-term efficacy for treatment-resistant depression, with meaningfully support from clinicial trials, particularly for IV racemic ketamine
• Longer-term management, the precise mechanism of benefit, and head-to-head comparisons between ketamien formulations remain open questions

---

Frequently Asked Questions

---

Related Articles in This Series

• Ketamine and the LGBTQ Community
• Harm Reduction at Magnetic World Festival
• Harm Reduction at Pride: A Coast to Coast Guide

---